Log in to save to my catalogue

The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter r...

The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter r...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8604725

The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial

About this item

Full title

The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial

Publisher

New York: Nature Publishing Group US

Journal title

Nature medicine, 2021-11, Vol.27 (11), p.1954-1960

Language

English

Formats

Publication information

Publisher

New York: Nature Publishing Group US

More information

Scope and Contents

Contents

Patients with heart failure and preserved ejection fraction (HFpEF) have a high burden of symptoms and functional limitations, and have a poor quality of life. By targeting cardiometabolic abmormalities, sodium glucose cotransporter 2 (SGLT2) inhibitors may improve these impairments. In this multicenter, randomized trial of patients with HFpEF (NCT...

Alternative Titles

Full title

The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8604725

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8604725

Other Identifiers

ISSN

1078-8956,1546-170X

E-ISSN

1546-170X

DOI

10.1038/s41591-021-01536-x

How to access this item